Top

Published in:

01-06-2015 | Original Article

Risk factors associated with Clostridium difficile infection in adult oncology patients

Authors: Analia Rodríguez Garzotto, Antonio Mérida García, Nerea Muñoz Unceta, M. Mar Galera Lopez, M. Ángeles Orellana-Miguel, C. Vanesa Díaz-García, Susana Cortijo-Cascajares, Hernán Cortes-Funes, M. Teresa Agulló-Ortuño

Published in: Supportive Care in Cancer | Issue 6/2015

Abstract

Purpose

Clostridium difficile infection (CDI) prevention is particularly important for cancer patients, because diarrhea often results in dose reductions or delays of chemotherapy or radiotherapy. We conducted this study to better ascertain the incidence, susceptibility, and risk factors for CDI in cancer patients receiving chemotherapy at our hospital.

Methods

We performed a retrospective study among adult cancer patients admitted at “12 de Octubre” University Hospital between January 2009 through April 2013 who were diagnosed with diarrhea. Inpatient data were available on hospital medical records. We screened by immunochromatography system detecting glutamate dehydrogenase antigen, and C. difficile toxins A and B. Later, a polymerase chain reaction for detecting toxin B gene was performed.

Results

A total of 225 patients were included in the study, and 39 of them (17.3 %) were diagnosed with CDI. Type of tumor significantly differed between CDI patients, thus relative risk in each type of cancer was calculated after adjusting for age, antibiotic exposure, corticosteroid, and proton-pump inhibitor use. Patients with gastrointestinal tumors were less prone to CDI. Conversely, breast cancer patients have a greater predisposition to CDI. Antibiotic treatment was found to be associated with an increasing risk for CDI in breast cancer patients. Curiously, exposure to proton-pump inhibitors appeared protective in our cohort, except for lung cancer patients. However, we have not been able to find an association between a particular type of chemotherapy and CDI.

Conclusions

We underscore the urgent need for early recognition and diagnosis of CDI in cancer patients. Our findings indicate a probable association between antibiotic use and CDI incidence, at least in certain cancer, such as breast cancer.

Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O’Connor L et al (2013) Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 369:1195–1205. doi:10.1056/NEJMoa1216064 CrossRefPubMed

Khan A, Raza S, Batul SA, Khan M, Aksoy T, Baig MA, Berger BJ (2012) The evolution of Clostridium difficile infection in cancer patients: epidemiology, pathophysiology, and guidelines for prevention and management. Recent Pat Antiinfect Drug Discov 7:157–170CrossRefPubMed

Lipp MJ, Nero DC, Callahan MA (2012) Impact of hospital-acquired Clostridium difficile. J Gastroenterol Hepatol 27:1733–1737. doi:10.1111/j.1440-1746.2012.07242.x CrossRefPubMed

Karas JA, Enoch DA, Aliyu SH (2010) A review of mortality due to Clostridium difficile infection. J Infect 61:1–8. doi:10.1016/j.jinf.2010.03.025 CrossRefPubMed

Mezoff EA, Cohen MB (2013) Acid suppression and the risk of Clostridium difficile infection. J Pediatr 163:627–630. doi:10.1016/j.jpeds.2013.04.047 CrossRefPubMedCentralPubMed

Kim JS, Ward KK, Shah NR, Saenz CC, McHale MT, Plaxe SC (2013) Excess risk of Clostridium difficile infection in ovarian cancer is related to exposure to broad-spectrum antibiotics. Support Care Cancer 21:3103–3107. doi:10.1007/s00520-013-1888-2 CrossRefPubMed

Kelly CP, LaMont JT (2008) Clostridium difficile — more difficult than ever. N Engl J Med 359:1932–1940. doi:10.1056/NEJMra0707500 CrossRefPubMed

Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S (2013) Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 31:2493–2499. doi:10.1200/JCO.2012.45.5899 CrossRefPubMed

Zwielehner J, Lassl C, Hippe B, Pointner A, Switzeny OJ, Remely M, Kitzweger E, Ruckser R, Haslberger AG (2011) Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting. PLoS One 6:e28654. doi:10.1371/journal.pone.0028654 CrossRefPubMedCentralPubMed

10.

Morotomi N, Fukuda K, Nakano M, Ichihara S, Oono T, Yamazaki T, Kobayashi N, Suzuki T, Tanaka Y, Taniguchi H (2011) Evaluation of intestinal microbiotas of healthy Japanese adults and effect of antibiotics using the 16S ribosomal RNA gene based clone library method. Biol Pharm Bull 34:1011–1020CrossRefPubMed

11.

Stringer AM, Gibson RJ, Bowen JM, Keefe DM (2009) Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab 10:79–83CrossRefPubMed

12.

van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ (2010) The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog 6:e1000879. doi:10.1371/journal.ppat.1000879 CrossRefPubMedCentralPubMed

13.

Raza S, Baig MA, Russell H, Gourdet Y, Berger BJ (2010) Clostridium difficile infection following chemotherapy. Recent Pat Antiinfect Drug Discov 5:1–9CrossRefPubMed

14.

Bishop KD, Castillo JJ (2012) Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk Lymphoma 53:1617–1619. doi:10.3109/10428194.2012.654472 CrossRefPubMed

15.

Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N et al (2011) Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365:1693–1703. doi:10.1056/NEJMoa1012413 CrossRefPubMed

16.

Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079–1084. doi:10.1016/S0140-6736(05)67420-X CrossRefPubMed

17.

Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A (2014) Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 306:G310–G319. doi:10.1152/ajpgi.00282.2013 CrossRefPubMedCentralPubMed

18.

Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, Thota P, Sferra TJ, Hernandez AV (2012) Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 10:225–233. doi:10.1016/j.cgh.2011.09.030 CrossRefPubMed

19.

Nesher L, Rolston KV (2013) Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis 56:711–717. doi:10.1093/cid/cis998 CrossRefPubMed

20.

Stewart DB, Yacoub E, Zhu J (2012) Chemotherapy patients with C. difficile colitis have outcomes similar to immunocompetent C. difficile patients. J Gastrointest Surg 16:1566–1572. doi:10.1007/s11605-011-1783-4 CrossRefPubMed

21.

Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B (2009) Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 30:253–264. doi:10.1111/j.1365-2036.2009.04037.x CrossRefPubMed

22.

Orellana-Miguel MA, Alcolea-Medina A, Barrado-Blanco L, Rodriguez-Otero J, Chaves-Sanchez F (2013) Algorithm proposal based on the C. Diff Quik Chek Complete ICT device for detecting Clostridium difficile infection. Enferm Infecc Microbiol Clin 31:97–99. doi:10.1016/j.eimc.2012.01.003 CrossRefPubMed

23.

Stein A, Voigt W, Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2:51–63. doi:10.1177/1758834009355164 CrossRefPubMedCentralPubMed

24.

Hautmann MG, Hipp M, Kolbl O (2011) Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment? Radiat Oncol 6:89. doi:10.1186/1748-717X-6-89 CrossRefPubMedCentralPubMed

25.

Hwang KE, Hwang YR, Seol CH, Park C, Park SH, Yoon KH, Park DS, Lee MK, Jeong ET, Kim HR (2013) Clostridium difficile infection in lung cancer patients. Jpn J Infect Dis 66:379–382CrossRefPubMed

26.

Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK (2012) Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 107:1011–1019. doi:10.1038/ajg.2012.108 CrossRefPubMed

27.

Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN (2012) Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 107:1001–1010. doi:10.1038/ajg.2012.179 CrossRefPubMed

28.

Reimer C (2013) Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol 27:443–454. doi:10.1016/j.bpg.2013.06.001 CrossRefPubMed

29.

Heidelbaugh JJ, Metz DC, Yang YX (2012) Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract 66:582–591. doi:10.1111/j.1742-1241.2012.02921.x CrossRefPubMed

30.

Chopra T, Alangaden GJ, Chandrasekar P (2010) Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 8:1113–1119. doi:10.1586/eri.10.95 CrossRefPubMed

31.

Baier R, Morphis B, Marsella M, Mermel LA (2013) Clostridium difficile surveillance: a multicenter comparison of LabID events and use of standard definitions. Infect Control Hosp Epidemiol 34:653–655. doi:10.1086/670642 CrossRefPubMed

Title: Risk factors associated with Clostridium difficile infection in adult oncology patients
Authors: Analia Rodríguez Garzotto
Antonio Mérida García
Nerea Muñoz Unceta
M. Mar Galera Lopez
M. Ángeles Orellana-Miguel
C. Vanesa Díaz-García
Susana Cortijo-Cascajares
Hernán Cortes-Funes
M. Teresa Agulló-Ortuño
Publication date: 01-06-2015
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 6/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2506-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2015

Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model

Prediction of short- and long-term survival for advanced cancer patients after ICU admission

Supportive care needs and preferences of lung cancer patients: a semi-structured qualitative interview study

The relationship between oral mucositis and levels of pro-inflammatory cytokines in serum and in gingival crevicular fluid in allogeneic stem cell recipients

Clinical approach in the management of oral chronic graft-versus-host disease (cGVHD) in a series of specialized medical centers

Bisphosphonate therapy in metastatic carcinoma patients with chronic renal failure: are bisphosphonates an enemy or crony?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer